SpyGlass Pharma reported total assets of $243.43M and total liabilities of $11.07M for the quarter ended Jun 2026. This balance sheet covers 4 quarters of results from Dec 2024 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Balance Sheet | Dec2024 | Jun2025 | Dec2025 | Jun2026 |
|---|---|---|---|---|
| Assets | ||||
| Current Assets | ||||
| Cash & EquivalentsCash & Equiv. | 16.27M | 96.36M | 223.14M | |
| Receivables - OtherOther Receivables | 0.42M | 0.43M | 0.68M | |
| Prepaid Assets | 0.71M | 0.90M | 1.60M | |
| Current Assets | 17.41M | 108.77M | 236.46M | |
| Non-Current Assets | ||||
| Property, Plant & Equipment (Net) | 2.17M | 2.34M | 4.79M | |
| Other Non-Current Assets | 0.45M | 0.49M | 0.76M | |
| Non-Current Assets | 5.91M | 7.10M | 6.97M | |
| Assets | 23.32M | 115.87M | 243.43M | |
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts Payables | 1.98M | 2.70M | 4.16M | |
| Payables | 1.98M | 2.70M | 4.16M | |
| Accumulated Expenses | 1.28M | 2.18M | 1.72M | |
| Other Accumulated Expenses | 0.67M | 3.71M | 3.56M | |
| Current Leases | 0.44M | |||
| Total Current Liabilities | 7.79M | 8.58M | 9.44M | |
| Non-Current Liabilities | ||||
| Non-Current Deffered Revenue | 2.71M | |||
| Preferred Stock Liabilities | 72.55M | 204.54M | 204.54M | |
| Operating Leases | 3.46M | 1.58M | 1.63M | |
| Total Liabilities | 11.25M | 78.38M | 10.17M | 11.07M |
| Shareholder's Equity | ||||
| Common Equity | -60.47M | -78.38M | -98.84M | 232.36M |
| Liabilities and Shareholders Equity | 23.32M | 115.87M | 243.43M | |
| Retained Earnings | -64.86M | -104.73M | 370.78M | |
| Treasury Shares | 9.61M | 20.34M | 20.34M |